Non-CYP metabolism. However, side effects such as nausea and vomiting may be potentially porphyrinogenic through reduction in caloric intake.

Nelarabine is a precursor to the deoxyguanosine analogue ara-G.

Nelarabine is an antimetabolite antineoplastic agent used to treat therapy-resistent acute lymphocytic leucemia of T-cell type and T-cell lymphoblastic lymphoma. Administered as intravenous infusion. Common adverse reactions of nalarabine that can be confused with an acute porphyric attack are nausea, vomiting, obstipation, diarrhoea, abdominal pain and myalgia. Side effects such as nausea and vomiting may be potentially porphyrinogenic through reduction in caloric intake.

Nelarabine is rapidly and extensively converted by demethylation to the cytotoxic guanine arabinoside that has a half life elimination time from plasma of 3 hours. Nelarabine also undergoes hydrolysis to form methylguanine. Both methylguanine and guanine arabinoside are further metabolized to guanine, which is deaminated to form xantine and finally oxidized to uric acid. Nelarabine does not appear to substantially inhibit any of the cytochrome P-450 (CYP) isoenzymes.

No.